AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 132 min read$GKOS

Gilliam Joseph E sold $10.8M of GKOS

Gilliam Joseph E (PRESIDENT & COO) sold 60,000 shares of GLAUKOS Corp (GKOS) at an average of $179.74 ($178.89–$180.49, $10.78M total) across 2 trades on 2026-08-11.

Original reporting
SEC EDGAR · Gilliam Joseph E
Published Aug 13, 2026, 11:57 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 11:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$GKOS
Neutral
medium confidence
Mentioned
$GKOS
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GKOSNeutralLow
01

Why it matters

The newest disclosed fact is the open-market sale of 60,000 shares on 2026-08-11 at $178.8900 to $180.4900, with holdings after the sale of 72,588 shares.

02

Market read

Traders may briefly reassess sentiment around GKOS due to insider selling, but there is no accompanying operational or financial catalyst in the text.

03

What to watch

Insider sales can be driven by diversification, pre-planned personal needs, or option/RSU mechanics not captured here; traders should check for other recent insider activity and any concurrent company news.

Relevance 7/10Novelty 4/10Timing: filed 2026-08-13 after trades dated 2026-08-11

Background

The article is a SEC Form 4 insider transaction disclosure for GLAUKOS Corp (GKOS) by its President and COO.

Company-level read

Ticker impact

$GKOSNeutralMedium confidence
Context

Form 4 shows GKOS COO sold 60,000 shares in open-market transactions totaling about $10.78M at ~$179.74 average.

Expected impact

Likely limited, short-lived sentiment impact; follow-through depends on broader news flow.

Evidence & confidence

The filing is a primary-source Form 4 disclosure with transaction size and pricing, but it does not include new guidance, contracts, or regulatory/clinical catalysts.

Market effects

Sector

No clear sector read-through from a single insider sale without additional company-specific developments.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The sale may be routine liquidity or tax-related, especially since it is not stated as part of a 10b5-1 plan, so it may not signal deteriorating fundamentals.

Key entities

  • issuer
    GLAUKOS Corp

    Company whose insider transaction is disclosed via Form 4.

  • insider
    Gilliam Joseph E

    President and COO who sold 60,000 shares in open-market transactions.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

GKOS insider trading history →

Related articles

OCT 9
$GKOSMed

Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal

Glaukos Corporation (GKOS) licensed RO-104, a tri-specific biologic for retinal diseases, from RevOpsis Therapeutics. The deal grants GKOS exclusive rights to RevOpsis' RevMod platform for up to four additional candidates. GKOS stock fell 6.3% post-announcement but is up 42.8% year-to-date. The agreement aims to expand GKOS' retinal therapeutics pipeline and market presence.

theglobeandmail.com3 min
OCT 9
$GKOSMed

Glaukos Corp (GKOS) Reports Positive Phase 4 Trial Results for i

Glaukos Corp (GKOS) reported positive phase 4 trial results for its iDose TR implant, showing significant reduction in intraocular pressure. The company trades at a P/S ratio of 15.24, above historical and industry medians, reflecting growth expectations. It has a GF Score of 79, indicating strong growth and financial health despite unprofitability. Insiders sold $67.8M in shares over the past year, while institutional investors increased holdings.

gurufocus.com2 min
OCT 9
$GKOSMed

Glaukos Reveals Superior Intraocular Pressure Reduction With Novel Eye Therapy - Glaukos (NYSE:GKOS)

Glaukos (NYSE:GKOS) reported positive Phase 4 trial results for its iDose TR therapy combined with cataract surgery. The treatment reduced intraocular pressure by 11.1 mmHg vs. 7.4 mmHg for surgery alone, meeting primary efficacy goals. The study showed no serious safety issues. The therapy aims to improve patient compliance with long-lasting drug delivery. GKOS shares are up 0.12% at $161.49.

benzinga.com2 min
OCT 9
$GKOSMedAI 9/10

Glaukos Reports Positive Phase 4 Results for iDose TR

Glaukos Corp. reported positive Phase 4 results for its iDose TR glaucoma treatment, meeting the primary endpoint and showing superiority in reducing intraocular pressure. The company also secured an exclusive licensing agreement with RevOpsis Therapeutics for retinal disease treatments. Shares of Glaukos (GKOS) were trading at $161.16 with a $9.5 billion market cap.

ocbj.com2 min